Kayothera Announces Expansion of Clinical Advisory Board
Key opinion leaders in beta-cell health and type 2 diabetes added to the Clinical Advisory Board.
Media inquiries →News
Science, company, and pipeline updates
Recent milestones from across Kayothera's platform, programs, and expert network.
Science
A nuclear target to revive anti-tumor immunity
Research advances understanding of how all-trans retinoic acid compromises anti-cancer immunity.
Media inquiries →Publication
Development of retinoid nuclear receptor pathway antagonists through targeting ALDH1A3
Foundational iScience research on drugging the retinoid nuclear receptor pathway.
Media inquiries →Pipeline
KAYO-1732 nominated as a development candidate
KAYO-1732 selected for type 2 diabetes and cardiometabolic indications.
Media inquiries →Recognition
ADA Innovation Challenge recognition
Kayothera recognized by the American Diabetes Association Innovation Challenge.
Media inquiries →Advisory
Scientific Advisory Board expansion
Yibin Kang, PhD chairs a Scientific Advisory Board with translational development expertise.
Media inquiries →Board
New Board appointments
Bruce L.A. Carter, PhD and Paul Sekhri joined the Board of Directors.
Media inquiries →Publication
JEM review on retinoid nuclear receptor signaling
A major review on cancer and metabolic syndromes by Esposito, Amory, and Kang.
Media inquiries →Connect with Kayothera